TNFRSF9 and head and neck squamous cell carcinoma: All these data suggest that the subset of CD137+ T cells could be considered as a potential biomarker for the response of (R/M) HNSCC patients to pembrolizumab treatment and serve as a useful tool to identify patients for whom pembrolizumab treatment would improve clinical status.